Veru

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Veru sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 4 completed top decile by trial count

Veru: 10 sponsored US clinical trials, 1 recruiting.

Veru sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 4 completed. 4 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is SARS-CoV Infection, with 1 trials.

Top-decile sponsor footprint

Veru ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 4
Phase 3 4

Therapeutic Areas

What is open in the Veru pipeline

1 recruiting of 10 indexed (10% open); 4 completed (40%).

Phase mix: 4 late (III/IV) vs 6 early (I/II) (balanced across stages).

Top condition: SARS-CoV Infection (1 trial), 0 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Veru: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Veru sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share VeruAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Veru sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Veru sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this Veru page

10 registered trials is a research-attention snapshot, not an endorsement of Veru or any single study.

  • 1 of Veru's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • SARS-CoV Infection is the condition Veru studies most, compare against other sponsors active in the same condition before evaluating a specific study. See SARS-CoV Infection trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Veru pipeline card: 10 registered trials from official public datasets.Report a data error.